Zoetis (ZTS) Other Non-Current Liabilities (2012 - 2026)
Zoetis' (ZTS) quarterly Other Non-Current Liabilities came in at $288.0 million in Q2 2026, up 5.11% year-over-year from $274.0 million in Q2 2025, and up 2.49% quarter-over-quarter from $281.0 million in Q1 2026.
Analysis
Zoetis (ZTS) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has reported Other Non-Current Liabilities for 15 consecutive years, with $288.0 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Other Non-Current Liabilities rose 5.11% year-over-year to $288.0 million in Q2 2026; TTM through Jun 2026 was $288.0 million, a 5.11% increase from a year earlier, with the FY2025 full-year figure at $276.0 million, up 1.47% from the prior year.
- Other Non-Current Liabilities was $288.0 million for Q2 2026 at Zoetis, up from $281.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $288.0 million in Q2 2026 and troughed at $241.0 million in Q3 2022.
- A 5-year average of $268.4 million and a median of $271.5 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities fell 6.95% in 2022 and rose 11.2% in 2023, its largest moves.
- Over 5 years, Other Non-Current Liabilities stood at $258.0 million in 2022, then advanced by 5.04% to $271.0 million in 2023, then increased by 0.37% to $272.0 million in 2024, then climbed by 1.47% to $276.0 million in 2025, then gained by 4.35% to $288.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $288.0 million (Q2 2026), $281.0 million (Q1 2026), and $276.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Idexx Laboratories | 40.69 Bn | 40.49 Bn | 779.09 Mn |
| 2 | Zoetis | 30.63 Bn | 28.95 Bn | 1.05 Bn |
| 3 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn |
| 4 | Phibro Animal Health | 1.49 Bn | 1.41 Bn | 134.40 Mn |
| 5 | Immucell | 90.19 Mn | 81.33 Mn | 2.44 Mn |
| 6 | Zhengye Biotechnology Holding | 76.23 Mn | 69.14 Mn | - |
| 7 | Global Innovative Platforms | 24.88 Mn | 24.63 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 288.00 Mn |
| Mar 31, 2026 | 281.00 Mn |
| Dec 31, 2025 | 276.00 Mn |
| Sep 30, 2025 | 270.00 Mn |
| Jun 30, 2025 | 274.00 Mn |
| Mar 31, 2025 | 277.00 Mn |
| Dec 31, 2024 | 272.00 Mn |
| Sep 30, 2024 | 274.00 Mn |
| Jun 30, 2024 | 267.00 Mn |
| Mar 31, 2024 | 277.00 Mn |
| Dec 31, 2023 | 271.00 Mn |
| Sep 30, 2023 | 262.00 Mn |
| Jun 30, 2023 | 278.00 Mn |
| Mar 31, 2023 | 262.00 Mn |
| Dec 31, 2022 | 258.00 Mn |
| Sep 30, 2022 | 241.00 Mn |
| Jun 30, 2022 | 250.00 Mn |
| Mar 31, 2022 | 254.00 Mn |
| Dec 31, 2021 | 257.00 Mn |
| Sep 30, 2021 | 259.00 Mn |